Xenon Pharmaceuticals Inc (XENE) Unusual Options Activity Today

Checking XENE unusual options activity helps you spot when traders are making outsized bets on Xenon Pharmaceuticals Inc before the broader market catches on. Xenon Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor XENE unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching XENE unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking XENE unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and XENE unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials.

It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Catalysts rarely arrive without a footprint, and XENE unusual options activity is often where that footprint shows up first. Our scanner tracks Xenon Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at XENE unusual options volume on the call side or chasing put sweeps, Xenon Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.